| [Psilocybin compared with escitalopram for depression].Ned Tijdschr Geneeskd | PMID 35138714无 PMCID | 2022-Jan-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.Int J Cancer | PMID 34528705PMC8627468 | 2022-Jan-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.Lancet | PMID 34953526PMC8700283 | 2022-Jan-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.Blood | PMID 34758069无 PMCID | 2022-Jan-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA | PMID 35015037PMC8753508 | 2022-Jan-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.J Clin Oncol | PMID 34648352无 PMCID | 2022-Jan-10 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.J Clin Oncol | PMID 34793245PMC8718175 | 2022-Jan-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.J Clin Oncol | PMID 34818112PMC8718224 | 2022-Jan-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology.J Hematol Oncol | PMID 35012610PMC8744064 | 2022-Jan-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial.Dis Esophagus | PMID 34155501无 PMCID | 2022-Jan-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.N Engl J Med | PMID 34986284无 PMCID | 2022-Jan-06 | 0.95 | The study meets most criteria (randomized, phase 3, drug intervention, time-to-event endpoint, original result) but is not an oncology study; it is for severe aplastic anemia, a non-malignant hematologic condition. Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort. | 待处理 |
| Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med | PMID 34986285PMC9844513 | 2022-Jan-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication.N Engl J Med | PMID 34986286PMC7612200 | 2022-Jan-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).Mod Rheumatol | PMID 33274687无 PMCID | 2022-Jan-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.JAMA Netw Open | PMID 35084480PMC8796017 | 2022-Jan-04 | 0.95 | The study meets most criteria (Phase III, randomized, oncology, human, drug intervention, original result) but does not have a primary/key secondary time-to-event efficacy endpoint. The primary endpoint is a count of days of neutropenia, and other endpoints are safety, infection rates, and patient-reported outcomes, none of which are time-to-event efficacy measures. | 待处理 |
| A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).Vaccine | PMID 34507861无 PMCID | 2022-Jan-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study.Platelets | PMID 33251910无 PMCID | 2022-Jan-02 | 0.90 | The study is a Phase III randomized trial of a drug for chronic immune thrombocytopenia, but it is not an oncology/malignant neoplasm study and does not have a time-to-event primary/key secondary endpoint. | 待处理 |
| Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.Haematologica | PMID 33297668PMC8719065 | 2022-Jan-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.Ann Surg | PMID 33630475无 PMCID | 2022-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial.Int J Radiat Oncol Biol Phys | PMID 34419564PMC8688221 | 2022-Jan-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).Int J Cancer | PMID 34431518无 PMCID | 2022-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Vitamin D Supplementation Improves Fasting Insulin Levels and HDL Cholesterol in Infertile Men.J Clin Endocrinol Metab | PMID 34508607无 PMCID | 2022-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.AIDS | PMID 34534138PMC8654248 | 2022-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating.Am J Gastroenterol | PMID 34585675PMC8715996 | 2022-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.J Clin Oncol | PMID 34606378PMC8683240 | 2022-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.JAMA Cardiol | PMID 34643642PMC8515258 | 2022-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial.JAMA Oncol | PMID 34695841PMC8546620 | 2022-Jan-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.JAMA Neurol | PMID 34807243PMC8609465 | 2022-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.Int J Radiat Oncol Biol Phys | PMID 34919884PMC8789217 | 2022-Jan-01 | 0.95 | This is a randomized Phase 3 trial in oncology with original results, but it compares two radiotherapy dose levels (70.2 Gy vs 79.2 Gy) without a drug-containing intervention. Furthermore, the primary endpoints are patient-reported quality-of-life outcomes, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the criteria for a Kaplan-Meier digitization cohort. | 待处理 |
| Randomized trial of azithromycin to eradicate Ureaplasma respiratory colonization in preterm infants: 2-year outcomes.Pediatr Res | PMID 33658655PMC8413397 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Methodology of the fatigue after stroke educational recovery group randomized controlled trial.Int J Stroke | PMID 33724101无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors.Diabetes Metab J | PMID 33866774PMC8831807 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.Ophthalmology | PMID 33957183无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.Br J Dermatol | PMID 33991341PMC9291944 | 2022-Jan | 0.95 | The study is a randomized Phase III trial with a drug intervention (risankizumab) and reports original efficacy results. However, it evaluates plaque psoriasis, which is a non-oncological condition. Therefore, it does not meet the primary oncology eligibility criterion. | 待处理 |
| Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.Allergy | PMID 33993501PMC9290136 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.Arthritis Rheumatol | PMID 34164944PMC9300099 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.Leukemia | PMID 34168284PMC8727292 | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| RESUME-1: a Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back.Pain Manag | PMID 34192885无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.Clin Lung Cancer | PMID 34226144无 PMCID | 2022-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexent.J Clin Pharm Ther | PMID 34263472无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.Br J Dermatol | PMID 34289086PMC9298328 | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.Am J Ophthalmol | PMID 34289338无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.Leukemia | PMID 34304248PMC8727301 | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Post-mastectomy Radiation Therapy in Triple-Negative Breast Cancer Patients: Analysis of the BEATRICE Trial.Ann Surg Oncol | PMID 34324113无 PMCID | 2022-Jan | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.J Am Acad Dermatol | PMID 34343599无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.Gastric Cancer | PMID 34351555无 PMCID | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.J Am Acad Dermatol | PMID 34416294无 PMCID | 2022-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Respir Med | PMID 34454653无 PMCID | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.Gastric Cancer | PMID 34468869PMC8732941 | 2022-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases.J Pathol Clin Res | PMID 34480530PMC8682940 | 2022-Jan | 0.85 | The record describes a randomized Phase III oncology trial in humans (EORTC 40983). However, the outcomes assessed are histopathological growth patterns and tumor regression grading, which are biomarkers, not the required survival, progression, recurrence, death, or time-to-event efficacy outcomes. Therefore, it is excluded. | 待处理 |